Newsroom
latest news from ose
and across our portfolio
Featured News
All News
Portfolio NewsPepGenPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyPortfolio NewsPepGenPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyPortfolio NewsPepGenPepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockPortfolio NewsPepGenMary Beth DeLena Joins PepGen as General Counsel and SecretaryPortfolio NewsPepGenPepGen Announces First Patient Dosed in Phase 2 Clinical Trial for Duchenne Muscular Dystrophy PatientsPortfolio NewsPepGenPepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)Portfolio NewsPepGenPepGen Announces Appointment of Howard Mayer, M.D. to Board of DirectorsPortfolio NewsPepGenPepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug ApplicationPortfolio NewsPepGenPepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1Portfolio NewsPepGenPepGen Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsPortfolio NewsPepGenPepGen announces IND-enabling preclinical data supporting progression of PGN-EDODM1 into clinical studiesPortfolio NewsPepGenPepGen announces positive preclinical data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, three novel duchenne muscular dystrophy candidatesPortfolio NewsPepGenPepGen reports third quarter 2022 financial results and recent corporate developmentsPortfolio NewsPepGenPepGen presents data from its Duchenne Muscular Dystrophy program at World Muscle Society CongressPortfolio NewsPepGenPepGen reports positive data from Phase 1 trial of PGN-ED051 for the treatment of Duchenne Muscular DystrophyPortfolio NewsPepGenPepGen appoints Habib Dable to Board of DirectorsPortfolio NewsPepGenPepGen reports second quarter 2022 financial results and recent corporate developmentsPortfolio NewsPepGenPepGen appoints Caroline Godfrey, Ph.D. to the company's scientific advisory boardPortfolio NewsPepGenPepGen reports first quarter 2022 financial results and recent corporate developmentsPortfolio NewsPepGenPepGen announces pricing of initial public offeringPortfolio NewsPepGenPepGen announces first participant dosed in a Phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular DystrophyPortfolio NewsPepGenPepGen appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical DevelopmentPortfolio NewsPepGenPepGen continues to build leadership team with additions of Senior Vice President, Clinical Operations and Vice President, ToxicologyPortfolio NewsPepGenPepGen announces approval by Health Canada of CTA to begin first in human trials of PGN-EDO51 to treat Duchenne Muscular DystrophyPortfolio NewsPepGenPepGen bolsters R&D team with appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical DevelopmentPortfolio NewsPepGenPepGen appoints Noel Donnelly as Chief Financial OfficerPortfolio NewsPepGenPepGen announces new additions to leadership team and Board of DirectorsPortfolio NewsPepGenPepGen announces closing of $112.5 million crossover financing to advance transformative therapies for neuromuscular diseasesPortfolio NewsPepGenPepGen strengthens leadership team with SVP of Chemistry, Manufacturing & Controls and VP of Finance AppointmentsPortfolio NewsPepGenPepGen announces formation of scientific advisory boardPortfolio NewsPepGenPepGen appoints James McArthur, Ph.D., as President and Chief Executive OfficerPortfolio NewsPepGenPepGen raises $45M in Series A funding, led by RA Capital